Jessica Couch, PhD

Hennig M, Bhattacharjee RB, Agarwal I, Alfaifi A, Casillas JE, Chavez S, Ishimaru D, Liston D, Mohapatra S, Molla T, Pathare S, Sidhu MS, Wang P, Wang Z, Lombana TN, Kharitonov VG, Couch JA, Lockhart DJ, Wustman BA. Inhaled DNAI1 mRNA therapy for treatment of primary ciliary dyskinesia. Proc Natl Acad Sci U S A. 122(18):e2421915122.

Katz JS, Rothstein JD, Cudkowicz ME, Genge A, Oskarsson B, Hains AB, Chen C, Galanter J, Burgess BL, Cho W, Kerchner GA, Yeh FL, Ghosh AS, Cheeti S, Brooks L, Honigberg L, Couch JA, Rothenberg ME, Brunstein F, Sharma KR, van den Berg L, Berry JD, Glass JD. A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS. Ann Clin Transl Neurol.

Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, Booler H, Bravo J, Brendza R, Brunstein F, Chan R, Chandra P, Couch JA, Datwani A, Demeule B, DiCara D, Erickson R, Ernst JA, Foreman O, He D, Hötzel I, Keeley M, Kwok MCM, Lafrance-Vanasse J, Lin H, Lu Y, Luk W, Manser P, Muhs A, Ngu H, Pfeifer A, Pihlgren M, Rao GK, Scearce-Levie K, Schauer SP, Smith WB, Solanoy H, Teng E, Wildsmith KR, Bumbaca Yadav D, Ying Y, Fuji RN, Kerchner GA. Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Science Translational Medicine. 13(593):eabb2639.

Mandikian D, Figueroa I, Oldendorp A, Rafidi H, Ulufatu S, Schweiger MG, Couch JA, Dybdal N, Joseph SB, Prabhu S, Ferl GZ, Boswell CA. Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology. AAPS Journal. 20/6.

Yadav DB, Maloney JA, Wildsmith KR, Fuji RN, Meilandt WJ, Solanoy H, Lu Y, Peng K, Wilson B, Chan P, Gadkar K, Kosky A, Goo M, Daugherty A, Couch JA, Keene T, Hayes K, Nikolas LJ, Lane D, Switzer R, Adams E, Watts RJ, Scearce-Levie K, Prabhu S, Shafer L, Thakker DR, Hildebrand K, Atwal JK. Widespread brain distribution and activity following ICV infusion of anti-β-secretase (BACE1) in nonhuman primates. British Journal of Pharmacology. 174(22):4173-4185.

Sewell F, Chapman K, Couch J, Dempster M, Heidel S, Loberg L, Maier C, Maclachlan TK, Todd M, van der Laan JW. Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use. mAbs. 9:5, 742-755.

Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes JM, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJ, Watts RJ, Couch JA, Meng YG, Atwal JK, Brezski RJ, Spiess C, Ernst JA. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem. 292(9):3900-3908.

Harstad E, Andaya R, Couch JA, Ding X, Liang X, Liederer BM, Messick K, Nguyen T, Schweiger MG, Tarrant JM, Zhong S, Dean BJ. Balancing blood sample volume with 3Rs: Implementation and best practices for small molecule toxicokinetic assessments in rats. ILAR Journal. 57:2, 157-16.

Gadkar K, Yadav DB, Zuchero JY, Couch JA, Kanodia J, Kenrick MK, Atwal JK, Dennis MS, Prabhu S, Watts RJ, Joseph SB, Ramanujan S. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain. European Journal of Pharmacology and Biopharmaceutics. 101:53-61.

Couch JA, Zhang G, Beyer JC, Zuch de Zafra C, Gupta P, Kamath AV, Lewin-Koh N, Tarrant J, Allamneni KA, Cain G, Yee S, Ross S, Cook R, Tsai SP, Ruppel J, Ridgway JB, Paluch M, Hass PE, Franklin J, Yan M. Balancing efficacy and safety of an anti-DLL4 antibody through pharmacokinetic modulation. Clinical Cancer Research.

Chapman K, Bayne K, Couch J, Decelle T, Finch J, de Hann L, Koban T, Mikkelsen LF, Muller W, Palmer H, Prescott M. Opportunities for implementing the 3Rs in drug development and safety assessment studies using nonhuman primates. In: The Nonhuman Primate in Drug Development and Safety Assessment. Elsevier.

Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Science Translational Medicine. 6(261):261ra154, 1-10.

Sewell F, Chapman K, Baldrick P, Brewster D, Broadmeadow A, Brown P, Burns-Naas LA, Clarke J, Constan A, Couch J, Czupalla O, Danks A, DeGeorge J, de Haan L, Hettinger K, Hill M, Festag M, Jacobs A, Jacobson-Kram D, Kopytek S, Lorenz H, Moesgaard SG, Moore E, Pasanen M, Perry R, Ragan I, Robinson S, Schmitt PM, Short B, Lima BS, Smith D, Sparrow S, van Bekkum Y, Jones D. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies. Regulatory Toxicology and Pharmacology. 70(1), 413-29.

Couch JA, Yu YJ, Zhang Y, Tarrant J, Fuji R, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia B, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst J, Dennis MS, Watts RJ. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Science Translational Medicine. 5(183):183ra57, 1-12.

Chapman KL, Holgreave H, Black L, Brown M, Chellman G, Copeman C, Cort N, Couch J, Creton S, Gehen S, Hoberman A, Kinter L, Madden S, Mattis C, Semple H, Wilson S. Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation. Regulatory Pharmacology and Toxicology. 66, 88-103.

Couch J, Taylor H, Chapman KL. Social housing for NHPs: A global perspective. In: Future Trends in Primate Toxicology and Biotechnology. GF Weinbauer and F Vogel, Eds.

Chapman KL, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Dempster MA, de Haan L, Jones K, Pullen N, Seitske de Boer A, Sims J, Ragan CI. The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in use of non-human primates. Regulatory Toxicology and Pharmacology. 62(2), 347-54.

Bussiere JL, Martin P, Horner M, Couch J, Flaherty M, Andrews L, Beyer J, Horvath C. Alternative strategies for toxicity testing of species-specific biopharmaceuticals. International Journal of Toxicology. 28(3), 230-253.

Miller JL, Couch J, Schwenk K, Long M, Towler S, Theriaque DW, He G, Liu Y, Driscoll DJ, Leonard CM. Early childhood obesity is associated with compromised cerebellar development. Developmental Neuropsychology. 34(3), 272-83.

Miller JL, Goldstone AP, Couch JA, Shuster J, Liu Y, He G, Driscoll DJ, Schmalfuss IM. Pituitary abnormalities in Prader-Willi Syndrome and early-onset morbid obesity. American Journal of Medical Genetics. 146(5), 570-7.

Miller JL, Couch JA, Goldstone AP, Towler SD, Shuster J, Schwenk K, He G, Driscoll DJ, Liu Y, Leonard CM. Sylvian fissure morphology in Prader-Willi Syndrome and early-onset morbid obesity. Genetics in Medicine. 9(8), 536-43.

Miller JL, James GA, Goldstone AP, Couch JA, He G, Driscoll DJ, Liu Y. Enhanced activation of reward-mediating prefrontal regions in response to food stimuli in Prader-Willi Syndrome. Journal of Neurology, Neurosurgery, and Psychiatry. 78(6), 615-9.

Miller JL, Couch JA, Schmalfuss I, He G, Liu Y, Driscoll DJ. Novel intracranial abnormalities detected by three-dimensional magnetic resonance imaging in Prader-Willi Syndrome. American Journal of Medical Genetics. 143(5), 476-83.

Couch JA, Chen J, Rieff HI, Uri EM, Condron BG. robo2 and robo3 interact with eagle to regulate serotonergic differentiation. Development. 131(5), 997-1106.

Couch J and Condron B. Axon guidance: Comm hither, Robo. Current Biology. 12(21), R741-2.